Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @mshadman
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @mshadman
-
Mazyar Shadman proslijedio/la je Tweet
Blown away as I watch a nearby community healthcare system implode due to management recommendations made by "consultants." Highly paid and highly powerful individuals who know nothing about patient care - driving up costs and breaking what they are paid to fix.pic.twitter.com/rZcFP2zcqt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Very interested in knowing
@Dmozaffarian's opinion about intermittent fasting.https://www.nejm.org/doi/full/10.1056/NEJMra1905136?query=TOC …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
Thrilled to see When Blood Breaks Down in the
@mitpress spring catalogue, now on-line! thank you@danielleofri for your support and the lovely sentiments!

https://mitpress.mit.edu/sites/default/files/inline-files/MITPress-S20-catalog-sm.pdf …pic.twitter.com/zySckJxWuv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
Very important study confirming what many of us have suspected for years - that antioxidant supplements impair chemotherapy efficacyhttps://ascopubs.org/doi/abs/10.1200/JCO.19.01203?journalCode=jco …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
This is the paper I’m most proud of having written in 2019. We can learn a lot from Bob.
#medtwitter@MayoClinic@MayoProceedingspic.twitter.com/nyVDpnLcEv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Seattle's rainiest day in the past decade!
#rain#seattlepic.twitter.com/cvkaDlDIbbHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Great essay by Dr. Kalaycio
@MattKalaycioMD. I was lucky to work with him when I was a resident on the leukemia service at the@ClevelandClinic (and Dr. Hamilton@hamiltkyb was our fellow!)https://www.mdedge.com/hematology-oncology/article/212811/business-medicine/resignation …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
Clonal hematopoiesis is a major source of somatic mutations detected in liquid biopsies of
#Cancer patients | http://go.nature.com/35aXgWT |#PrecisionMedicine#genomics@sloan_ketteringpic.twitter.com/yftDFIhEOG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
Antigen loss and tumor phenotype heterogeneity are significant obstacles to the success of
#CARTcell therapy. Balakrishnan A from Stan Riddell's lab@fredhutch explored Designed Ankyrin Repeat Proteins (DARPins) instead of scFv for multiantigen targeting https://clincancerres.aacrjournals.org/content/25/24/7506.long …pic.twitter.com/QG4OIQiBUP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
DLBCL pt in CR. Fit withdonor. Not many treatment options if relapses.
@DrJFriedberg@JohnPLeonardMD@MediHumdani@DrNathanFowler@BrianHill_MDPhD@graham74GC@BldCancerDoc@drkomanduri@DrAnasYounes@SoniSmithMD@DrDanPersky@DrLizBrem@DebbieMStephens@mana1981@MattKalaycioMDHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Very interested in knowing how other centers approach this situation
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
DLBCL s/p CART in CR (day90). fit with a donor. Not many options if relapses. alloSCT vs. observation?
@MediHumdani@DrJFriedberg@DrAnasYounes@JohnPLeonardMD@drkomanduri@DrDanPersky@graham74GC@BldCancerDoc@BrianHill_MDPhD@DrNathanFowler@gilles_salles@timfenskePrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Press release only:
#Zanubrutinib not superior to#ibrutinib in#WM. Better tox profile as expected.#CLL trial has finished enrollment.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent
#tweetorial by Dr. Fonseca (@Rfonsi1 ) on t(11;14) was solicited by@VincentRK for publication. Beginning of a new era?https://twitter.com/VincentRK/status/1206252053640744960 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je Tweet
We have to make it crystal clear: every cancer patient in the world is a human being like ourselves and deserves optimal therapy based on current evidence. Every patient.https://twitter.com/mshadman/status/1205708132019654656 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mazyar Shadman proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Glad this is a priority topic for
@iwCLL . Working on a project to show different outcomes in high-risk CLL pts in different countries in the novel agents era.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.